Zarate YA, Hopkin RJ. Fabry’s disease. Lancet. 2008;372:1427–35.

Article  CAS  PubMed  Google Scholar 

Spada M, Pagliardini S, Yasuda M, et al. High incidence of later-onset Fabry disease revealed by newborn screening. Am J Hum Genet. 2006;79:31–40.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gilchrist M, Casanova F, Tyrrell JS, et al. Prevalence of Fabry disease-causing variants in the UK Biobank. J Med Genet. 2023;60:391–6.

Article  CAS  PubMed  Google Scholar 

Eng CM, Fletcher J, Wilcox WR, et al. Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry. J Inherit Metab Dis. 2007;30:184–92.

Article  CAS  PubMed  Google Scholar 

Echevarria L, Benistan K, Toussaint A, et al. X-chromosome inactivation in female patients with Fabry disease. Clin Genet. 2016;89:44–54.

Article  CAS  PubMed  Google Scholar 

Germain DP. Fabry disease. Orphanet J Rare Dis. 2010;5:30.

Article  PubMed  PubMed Central  Google Scholar 

Ortiz A, Germain DP, Desnick RJ, et al. Fabry disease revisited: management and treatment recommendations for adult patients. Mol Genet Metab. 2018;123:416–27.

Article  CAS  PubMed  Google Scholar 

Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405–24.

Article  PubMed  PubMed Central  Google Scholar 

Wanner C, Arad M, Baron R, et al. European expert consensus statement on therapeutic goals in Fabry disease. Mol Genet Metab. 2018;124:189–203.

Article  CAS  PubMed  Google Scholar 

Biegstraaten M, Arngrímsson R, Barbey F, et al. Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document. Orphanet J Rare Dis. 2015;10:36.

Article  PubMed  PubMed Central  Google Scholar 

Brand E, Linhart A, Deegan P, et al. Clinical management of female patients with Fabry disease based on expert consensus. Orphanet J Rare Dis. 2025;20:7.

Article  PubMed  PubMed Central  Google Scholar 

Germain DP, Porto Vasconcelos A, Tran Thi Phuong L, et al. Safety and tolerability of a shorter agalsidase beta infusion time in patients with classic or later-onset Fabry disease. Biomedicines. 2024;12:2578.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lenders M, Brand E. Effects of enzyme replacement therapy and antidrug antibodies in patients with Fabry disease. J Am Soc Nephrol. 2018;29:2265–78.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mignani R, Biagini E, Cianci V, et al. Effects of current therapies on disease progression in Fabry disease: a narrative review for better patient management in clinical practice. Adv Ther. 2025;42(2):597–635. https://doi.org/10.1007/s12325-024-03041-2.

Article  PubMed  Google Scholar 

Figliozzi S, Kollia E, Simistiras A, et al. Effects of enzyme replacement therapy on cardiac MRI findings in Fabry disease: a systematic review and meta-analysis. Radiol Cardiothorac Imaging. 2024;6: e230154.

Article  PubMed  PubMed Central  Google Scholar 

Kampmann C, Perrin A, Beck M. Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years’ treatment. Orphanet J Rare Dis. 2015;10:125.

Article  PubMed  PubMed Central  Google Scholar 

Germain DP, Charrow J, Desnick RJ, et al. Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease. J Med Genet. 2015;52:353–8.

Article  CAS  PubMed  Google Scholar 

Schiffmann R, Swift C, Wang X, Blankenship D, Ries M. A prospective 10-year study of individualized, intensified enzyme replacement therapy in advanced Fabry disease. J Inherit Metab Dis. 2015;38:1129–36.

Article  CAS  PubMed  Google Scholar 

Lenders M, Hennermann JB, Kurschat C, et al. Multicenter Female Fabry Study (MFFS): clinical survey on current treatment of females with Fabry disease. Orphanet J Rare Dis. 2016;11:88.

Article  PubMed  PubMed Central  Google Scholar 

Lenders M, Nowak A, Cybulla M, et al. Impact of enzyme replacement therapy on clinical manifestations in females with Fabry disease. Orphanet J Rare Dis. 2024;19:490.

Article  PubMed  PubMed Central  Google Scholar 

Lenders M, Nowak A, Cybulla M, et al. Impact of enzyme replacement therapy and migalastat on disease progression in females with Fabry disease. Orphanet J Rare Dis. 2025;20:79.

Article  PubMed  PubMed Central  Google Scholar 

Germain DP, Elliott PM, Falissard B, et al. The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: a systematic literature review by a European panel of experts. Mol Genet Metab Rep. 2019;19: 100454.

PubMed  PubMed Central  Google Scholar 

Tøndel C, Bostad L, Larsen KK, et al. Agalsidase benefits renal histology in young patients with Fabry disease. J Am Soc Nephrol. 2013;24:137–48.

Article  PubMed  Google Scholar 

Weidemann F, Krämer J, Duning T, et al. Patients with Fabry disease after enzyme replacement therapy dose reduction versus treatment switch. J Am Soc Nephrol. 2014;25:837–49.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lenders M, Canaan-Kühl S, Krämer J, et al. Patients with Fabry disease after enzyme replacement therapy dose reduction and switch-2-year follow-up. J Am Soc Nephrol. 2016;27:952–62.

Article  CAS  PubMed  Google Scholar 

Skrunes R, Svarstad E, Kampevold Larsen K, Leh S, Tøndel C. Reaccumulation of globotriaosylceramide in podocytes after agalsidase dose reduction in young Fabry patients. Nephrol Dial Transplant. 2017;32:807–13.

CAS  PubMed  Google Scholar 

Krämer J, Lenders M, Canaan-Kühl S, et al. Fabry disease under enzyme replacement therapy-new insights in efficacy of different dosages. Nephrol Dial Transplant. 2018;33:1362–72.

Article  PubMed  Google Scholar 

Tøndel C, Thurberg BL, DasMahapatra P, et al. Clinical relevance of globotriaosylceramide accumulation in Fabry disease and the effect of agalsidase beta in affected tissues. Mol Genet Metab. 2022;137:328–41.

Article  PubMed  Google Scholar 

Morimoto H, Ito Y, Yoden E, et al. Non-clinical evaluation of JR-051 as a biosimilar to agalsidase beta for the treatment of Fabry disease. Mol Genet Metab. 2018;125:153–60.

Article  CAS  PubMed  Google Scholar 

Tsukimura T, Shiga T, Togawa T, Sakuraba H. Comparative study on incorporation of three recombinant human α-galactosidase A drugs (agalsidases) into cultured fibroblasts and organs/tissues of Fabry mice. Mol Genet Metab Rep. 2024;40: 101118.

CAS  PubMed  PubMed Central  Google Scholar 

Nakamura K, Kawashima S, Tozawa H, et al. Pharmacokinetics and pharmacodynamics of JR-051, a biosimilar of agalsidase beta, in healthy adults and patients with Fabry disease: phase I and II/III clinical studies. Mol Genet Metab. 2020;130:215–24.

Article  CAS  PubMed  Google Scholar 

van Kuilenburg ABP, Hollak CEM, Travella A, et al. Develop